Background: Findings are inconsistent regarding the degree to which depression may exert a negative impact on glycemic control in patients with type 2 diabetes. We therefore aimed to examine the longitudinal relationship between depression, behavioral factors, and glycemic control. Methods: In a prospective component of a nationally representative sample, 866 patients with type 2 diabetes aged ≧18 years completed a standardized assessment including a laboratory screening, questionnaires, and diagnostic measures. Subsequent to baseline (t₀), patients were tracked over a period of 12 months (t1). Depression was assessed according to DSM-IV and ICD-10 criteria. Glycemic control was determined by levels of glycosylated hemoglobin (HbA1c); a level of ≧7% was judged as unsatisfactory. Regression analyses were performed to analyze the prospective relationship between depression, medication adherence, diabetes-related health behavior, and HbA1c. Results: Patients with depression at t₀ revealed increased rates of medication nonadherence (adjusted OR: 2.67; CI: 1.38–5.15) at t1. Depression (adjusted regression coefficient: β = 0.96; p = 0.001) and subthreshold depression (β = 1.01; p < 0.001) at t₀ also predicted increased problems with diabetes-related health behavior at t1. Adjusted ORs for poor glycemic control (HbA1c ≧7%) at t1 were also increased for patients with baseline depression (2.01; CI: 1.10–3.69). However, problems with medication adherence as well as problems with diabetes-related health behavior at t₀ did not predict poor glycemic control at t1. Conclusions: In a prospective representative study of patients with type 2 diabetes, baseline depression predicted problems with medication adherence, problems with health-related behaviors, and unsatisfactory glycemic control at follow-up.

Keywords:
Diabetes, Nonadherence, Glycemic control
1.
Ali S, Stone M, Peters J, Davies M, Khunti K: The prevalence of comorbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006;11:1165–1173.
2.
de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ: Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619–630.
3.
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B: Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851–858.
4.
Kivimaki M, Vahtera J, Pentti J, Virtanen M, Elovainio M, Hemingway H: Increased sickness absence in diabetic employees: what is the role of co-morbid conditions? Diabet Med 2007;24:1043–1048.
5.
Simon GE, Katon WJ, Lin EH, Ludman E, VonKorff M, Ciechanowski P, Young BA: Diabetes complications and depression as predictors of health service costs. Gen Hosp Psychiatry 2005;27:344–351.
6.
Katon W, Fan MY, Unutzer J, Taylor J, Pincus H, Schoenbaum M: Depression and diabetes: a potentially lethal combination. J Gen Intern Med 2008;23:1571–1575.
7.
Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Roux AV, Lee HB, Lyketsos C: Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008;299:2751–2759.
8.
Knol MJ, Heerdink ER, Egberts AC, Geerlings MI, Gorter KJ, Numans ME, Grobbee DE, Klungel OH, Burger H: Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom Med 2007;69:300–305.
9.
Musselman DL, Betan E, Larsen H, Phillips LS: Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003;54:317–329.
10.
Gonzalez JS, Safren SA, Cagliero E, Wexler DJ, Delahanty L, Wittenberg E, Blais MA, Meigs JB, Grant RW: Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care 2007;30:2222–2227.
11.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.
12.
Trief PM, Morin PC, Izquierdo R, Teresi J, Eimicke JP, Goland R, Starren J, Shea S, Weinstock RS: Depression and glycemic control in elderly ethnically diverse patients with diabetes: the IDEATel project. Diabetes Care 2006;29:830–835.
13.
Engum A, Mykletun A, Midthjell K, Holen A, Dahl AA: Depression and diabetes: a large population-based study of sociodemographic, lifestyle, and clinical factors associated with depression in type 1 and type 2 diabetes. Diabetes Care 2005;28:1904–1909.
14.
Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE: Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934–942.
15.
Wittchen HU, Glaesmer H, März W, Stalla G, Lehnert H, Zeiher AM, Silber S, Koch U, Böhler S, Pittrow D, Ruf G: Cardiovascular risk factors in primary care: methods and baseline prevalence rates – the DETECT program. Curr Med Res Opin 2005;21:619–629.
16.
Wittchen HU, Perkonigg A: DIA-X-Screening Instruments: Questionnaire DIA-SSQ: Screening for Mental Disorders; Questionnaire DIA-ASQ: Screening for Anxiety Disorders; Questionnaire DIA-DSQ: Screening for Depression (in German). Frankfurt, Swets and Zeitlinger, 1997.
17.
Munk-Jorgensen P, Allgulander C, Dahl AA, Foldager L, Holm M, Rasmussen I, Virta A, Huuhtanen MT, Wittchen HU: Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv 2006;57:1738–1744.
18.
Höfler M, Wittchen H: Why do primary care doctors diagnose depression when diagnostic criteria are not met? Int J Methods Psychiatr Res 2000;9:110–120.
19.
World Health Organization: Composite International Diagnostic Interview (CIDI) 1.0. Geneva, WHO, 1990.
20.
Black SA, Markides KS, Ray LA: Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care 2003;26:2822–2828.
21.
American Diabetes Association: Standards of medical care in diabetes – 2006. Diabetes Care 2006;29(suppl 1):S4–S42.
22.
Royall RM: Model robust confidence intervals using maximum likelihood estimators. Int Stat Rev 1986;54:221–227.
23.
Katon W, von Korff M, Ciechanowski P, Russo J, Lin E, Simon G, Ludman E, Walker E, Bush T, Young B: Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care 2004;27:914–920.
24.
Gross R, Olfson M, Gameroff MJ, Carasquillo O, Shea S, Feder A, Lantigua R, Fuentes M, Weissman MM: Depression and glycemic control in Hispanic primary care patients with diabetes. J Gen Intern Med 2005;20:460–466.
25.
Fisher L, Skaff MM, Mullan JT, Arean P, Mohr D, Masharani U, Glasgow R, Laurencin G: Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. Diabetes Care 2007;30:542–548.
26.
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK: Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–47.
27.
Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB: The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 2003;25:246–252.
28.
Kravitz RL, Hays RD, Sherbourne CD, DiMatteo MR, Rogers WH, Ordway L, Greenfield S: Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med 1993;153:1869–1878.
29.
Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB: The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004;42:649–652.
30.
Cook CL, Perri M 3rd: Single-item versus multiple-item measures of stage of change in compliance with prescribed medications. Psychol Rep 2004;94:115–124.
31.
Peyrot M, Rubin RR: Persistence of depressive symptoms in diabetic adults. Diabetes Care 1999;22:448–452.
32.
Katon WJ, Simon G, Russo J, Von Korff M, Lin EH, Ludman E, Ciechanowski P, Bush T: Quality of depression care in a population-based sample of patients with diabetes and major depression. Med Care 2004;42:1222–1229.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.